Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Colorcon
McKesson
Harvard Business School
Baxter
Moodys
Argus Health
Deloitte
Cipla

Generated: May 20, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

« Back to Dashboard

Clinical Trials for betamethasone acetate; betamethasone sodium phosphate

Trial ID Title Status Sponsor Phase Summary
NCT00000115 Randomized Trial of Acetazolamide for Uveitis-Associated Cystoid Macular Edema Completed National Eye Institute (NEI) Phase 2 To test the efficacy of acetazolamide for the treatment of uveitis-associated cystoid macular edema.
NCT00000138 Herpetic Eye Disease Study (HEDS) I Unknown status National Eye Institute (NEI) Phase 3 To evaluate the efficacy of topical corticosteroids in treating herpes simplex stromal keratitis in conjunction with topical trifluridine. To evaluate the efficacy of oral acyclovir in treating herpes simplex stromal keratitis in patients receiving concomitant topical corticosteroids and trifluridine. To evaluate the efficacy of oral acyclovir in treating herpes simplex iridocyclitis in conjunction with treatment with topical corticosteroids and trifluridine.
NCT00000412 Osteoporosis Prevention After Heart Transplant Completed Merck Sharp & Dohme Corp. Phase 3 During the first year after a heart transplant, people often rapidly lose bone from their spine and hips. About 35 percent of people who receive heart transplants will suffer broken bones during the first year after transplantation. This study will compare the safety and effectiveness of the drug alendronate (Fosamax) and the active form of vitamin D (calcitriol) in preventing bone loss at the spine and hip after a heart transplant. In this study, people who have had a successful heart transplant will receive either active alendronate and a "dummy pill" instead of calcitriol, or active calcitriol and a dummy pill instead of alendronate for the first year after their transplant, starting within 1 month after transplant surgery. We will measure bone density in the hip and spine at the start of the study and after 6 and 12 months, and will also check for broken bones in the spine. This research should lead to ways of preventing this crippling form of osteoporosis.
NCT00000412 Osteoporosis Prevention After Heart Transplant Completed National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Phase 3 During the first year after a heart transplant, people often rapidly lose bone from their spine and hips. About 35 percent of people who receive heart transplants will suffer broken bones during the first year after transplantation. This study will compare the safety and effectiveness of the drug alendronate (Fosamax) and the active form of vitamin D (calcitriol) in preventing bone loss at the spine and hip after a heart transplant. In this study, people who have had a successful heart transplant will receive either active alendronate and a "dummy pill" instead of calcitriol, or active calcitriol and a dummy pill instead of alendronate for the first year after their transplant, starting within 1 month after transplant surgery. We will measure bone density in the hip and spine at the start of the study and after 6 and 12 months, and will also check for broken bones in the spine. This research should lead to ways of preventing this crippling form of osteoporosis.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Clinical Trial Conditions for betamethasone acetate; betamethasone sodium phosphate

Condition Name

Condition Name for betamethasone acetate; betamethasone sodium phosphate
Intervention Trials
Healthy 160
Prostate Cancer 138
Hypertension 66
Leukemia 63
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for betamethasone acetate; betamethasone sodium phosphate
Intervention Trials
Prostatic Neoplasms 224
Leukemia 169
Syndrome 159
Kidney Diseases 155
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for betamethasone acetate; betamethasone sodium phosphate

Trials by Country

Trials by Country for betamethasone acetate; betamethasone sodium phosphate
Location Trials
United States 8,849
Canada 647
Japan 333
United Kingdom 329
Germany 316
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for betamethasone acetate; betamethasone sodium phosphate
Location Trials
California 540
Texas 474
New York 462
Florida 375
Pennsylvania 342
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for betamethasone acetate; betamethasone sodium phosphate

Clinical Trial Phase

Clinical Trial Phase for betamethasone acetate; betamethasone sodium phosphate
Clinical Trial Phase Trials
Phase 4 819
Phase 3 868
Phase 2/Phase 3 115
[disabled in preview] 918
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for betamethasone acetate; betamethasone sodium phosphate
Clinical Trial Phase Trials
Completed 2164
Recruiting 651
Unknown status 311
[disabled in preview] 290
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for betamethasone acetate; betamethasone sodium phosphate

Sponsor Name

Sponsor Name for betamethasone acetate; betamethasone sodium phosphate
Sponsor Trials
National Cancer Institute (NCI) 317
Merck Sharp & Dohme Corp. 82
GlaxoSmithKline 79
[disabled in preview] 72
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for betamethasone acetate; betamethasone sodium phosphate
Sponsor Trials
Other 3435
Industry 2078
NIH 589
[disabled in preview] 53
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
UBS
Cantor Fitzgerald
Dow
Citi
Accenture
Mallinckrodt
Cipla
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.